Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

Pfizer

Status: Completed

Conditions: Breast Cancer

Treatments: Drug: Aromasin

Study type: Observational

Funder types: Industry

Identifiers

NCT01047358

A5991089

Details and patient eligibility

About

This non-interventional study is to monitor use in real practice in Korea including adverse events on Aromasin (Exemestane).

Full description

All cases at the participating institutions.

Enrollment: 206 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• • Postmenopausal women with breast cancer eligible for hormonal therapy.

Exclusion criteria

• Pregnant breast-feeding premenopausal.

Trial design

206 participants in 2 patient groups

ajuvant group

Description:

adjuvant setting after two to three years of tamoxifen

Treatment:

Drug: Aromasin

Drug: Aromasin

palliative group

Description:

palliative setting after progression of disease with anti-estrogen therapy

Treatment:

Drug: Aromasin

Drug: Aromasin